Tagged with Switzerland

Switzerland With 35 years’ experience in natural extracts, purified ingredients, semi-synthetic APIs of natural origin and manufacturing products to the highest standards of excellence and quality, Linnea is a ground-breaking company with a strong heritage that successfully accepts challenges in new segments while expanding its product portfolio. What changes in attitudes…

Switzerland Working at the convergence of information technology and operational technology, Rockwell helps clients to unlock value by giving them the right data to make smart decisions. For the life science industry in particular, there are many unexplored opportunities to unlock value within supply chains. The buzzword in automation is Industry…

Switzerland Working to stay ahead in the highly competitive medical device field, Boston Scientific’s Philippe Hügli launched a Customer Insight Initiative in Switzerland which has served as a pilot for the European organization.  Considering the immense competition in the medical device industry today, what do you see as the key trends…

Switzerland Lupin’s EMEA President Thierry Volle explains that to fuel growth in the EMEA region, Lupin is investing heavily in transforming the business from a generics company into a specialty pharma player. Mr Volle, given your background in the innovative pharma sector, what was it that attracted you to join Lupin?…

Switzerland Soho Flordis International (SFI) has the ambition to be a global leader in premium natural healthcare solutions, and is leveraging extensive M&A activities to reach this goal. Group head of business development Michele Genovesi discusses the group’s aims and strategy, and explains how Ticino based Ginsana SA – now SFI…

Switzerland Italian-speaking Swiss canton Ticino outperforms most regions within Europe, yet still lags behind the high-flying cantons of Northern Switzerland. Stefano Rizzi, director of the canton’s economic division, discusses its economic development strategy and the important role that the life sciences sector plays within it. Ticino is the Italian-speaking region of…

Switzerland With a population of only 350,000, Ticino has a remarkably well developed pharmaceutical cluster. FIT Chairman Giorgio Calderari explains that the cluster’s key strength lies in the diverse range of capabilities which its members are able to offer as contract services to one another, and of course other interested third…

Switzerland Niche generics manufacturer Rivopharm was nearly bankrupt when acquired by current president and CEO Piero Poli in 2005; he explains the changes and strategy he put in place to drive the company to over 5x growth in the last 12 years while successfully bringing the first generics of several niche…

Switzerland www.celonic.com CEO of Swiss biologics CDMO Celonic, Konstantin Matentzoglu, explains how the company attracts talented and experienced staff and what makes it the partner of choice in Switzerland and beyond. Celonic is in many ways more than a CDMO for biologics. What is the strategic focus of this company? “Our…

Switzerland As the largest privately owned pharmaceutical company in Switzerland, IBSA remains committed to continuing to invest and manufacture in Switzerland. Head of Swiss Business Operations Maleša Ulrico Sidjanski, MSc ETH, discusses the company’s current priorities, values, and upcoming investments.   What other mid-sized multinational pharmaceutical companies present in over 80…

Switzerland Jesús Martin-Garcia, Chairman and CEO of GeNeuro, discusses their positive partnership with Servier to develop an antibody against a possible cause of MS, as well as the reasons for choosing Geneva when working with multiple sclerosis. Following 15 years of research performed by French-based Institut Mérieux and INSERM, GeNeuro was…

Switzerland Managing volatility – the CEO of Acino, a Swiss pharmaceutical player, elaborates on the company’s unique strategy based on its significant expertise in volatile and uncertain key markets within their regions. Most of your career has been spent with mid-cap and big pharmaceutical companies. Three years ago, you decided to…